The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance

• Published in: Cancers Vol. 13; no. 5; p. 1014
• Main Authors: Heissig, Beate, Salama, Yousef, Takahashi, Satoshi, Okumura, Ko, Hattori, Koichi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-03-2021; MDPI
• Subjects: Angiogenesis; Apoptosis; Binding sites; Blood; Cancer; Cell adhesion & migration; Cell growth; Drug resistance; Endothelial cells; Endothelium; Epidermal growth factor; Extracellular matrix; Gene regulation; Kinases; Leukemia; Ligands; Liver cancer; Mesenchyme; Metastases; Metastasis; Phosphorylation; Proteins; Review; Therapeutic targets; Transcription; Transcription factors; Tumorigenesis; EGFL7; endothelial cells; angiocrine factor; proliferation; angiogenesis; adhesion; EMT; beta 3 integrin; ECM; EGFR; KLF2; protease; FAK; miR-126; LOX; migration; cancer; drug resistance; integrin
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13051014

Invasion of cancer cells into surrounding tissue and the vasculature is an important step for tumor progression and the establishment of distant metastasis. The extracellular matrix (ECM) is home to many biomolecules that support new vessel formation and cancer growth. Endothelial cells release growth factors such as epidermal growth factor-like protein-7 (EGFL7), which contributes to the formation of the tumor vasculature. The signaling axis formed by EGFL7 and one of its receptors, beta 3 integrin, has emerged as a key mediator in the regulation of tumor metastasis and drug resistance. Here we summarize recent studies on the role of the ECM-linked angiocrine factor EGFL7 in primary tumor growth, neoangiogenesis, tumor metastasis by enhancing epithelial-mesenchymal transition, alterations in ECM rigidity, and drug resistance. We discuss its role in cellular adhesion and migration, vascular leakiness, and the anti-cancer response and provide background on its transcriptional regulation. Finally, we discuss its potential as a drug target as an anti-cancer strategy.